Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection
The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.
Pseudomonas Aeruginosa Airway Infection
Drug: Aztreonam Lysine for Inhalation
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Expanded Access Program for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00499720
Show 65 Study Locations